AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesTechnology, Industry, AgricultureInformation ScienceHealth Care
MelphalanInterferonsInterferon-gammaInterferon Type IReceptors, InterferonChemotherapy, Cancer, Regional PerfusionAntineoplastic Agents, AlkylatingInterferon InducersInterferon-alphaMultiple MyelomaRecombinant ProteinsCytokinesInterferon-betaInterferon Regulatory Factor-1Cells, CulturedInterferon Regulatory Factor-3Transplantation, AutologousTumor Necrosis Factor-alphaCell LineInterferon Regulatory FactorsReceptor, Interferon alpha-betaSTAT1 Transcription FactorMice, Inbred C57BLMyeloablative AgonistsT-LymphocytesRNA, MessengerMice, Inbred BALB CInterleukin-4Molecular Sequence DataAntiviral AgentsDose-Response Relationship, DrugInterferon Regulatory Factor-7Interleukin-12Antineoplastic Combined Chemotherapy ProtocolsMacrophagesCarmustineGene Expression RegulationSpleenInterleukin-2Time FactorsPoly I-CBase SequenceHematopoietic Stem Cell TransplantationAmyloidosisDrug SynergismCD4-Positive T-LymphocytesPrednisoneTransplantation ConditioningTumor Cells, CulturedGamma RaysKiller Cells, NaturalInterferon Regulatory Factor-2Combined Modality TherapySignal TransductionFlow CytometryMelanomaNewcastle disease virusLymphocyte ActivationTh1 CellsInterleukinsInterleukin-10Mice, KnockoutLeukocytes, MononuclearTreatment OutcomeCyclophosphamideRibavirinGene ExpressionKineticsMisonidazoleThalidomideLipopolysaccharidesAntibodies, MonoclonalInterferon-gamma Release TestsButhionine SulfoximineMethionine SulfoximineAntineoplastic AgentsThiotepaVincristineDrug ResistanceDNA-Binding ProteinsAmino Acid SequenceMonocytesChemokine CXCL10Drug EvaluationInterferon-Stimulated Gene Factor 3Hepatitis C, ChronicImmunity, InnateTranscription, GeneticL Cells (Cell Line)Vesicular stomatitis Indiana virus2',5'-Oligoadenylate SynthetaseCell SurvivalMacrophage ActivationCD8-Positive T-LymphocytesImmunity, CellularDexamethasoneBoronic AcidsCell DivisionDrug Therapy, CombinationPyrazines
CorticosteroidsPrednisoneResponseIsolated limb perfPresent
Corticosteroids1
  • Until the year 2000, the standard therapy for MM was melphalan- or doxorubicin-based regimens with corticosteroids. (biomedcentral.com)
Prednisone1
  • In elderly patients or patients in whom autologous transplantation is not possible in the future, melphalan and prednisone (MP) therapy is preferred because of its ease of administration and low toxicity. (medscape.com)
Response1
  • Here, we find that persistent mtDNA stress is not associated with basally activated NF-κB signalling or interferon gene expression typical of an acute antiviral response. (regenerativemedicine.net)
Isolated limb perf6
  • 2. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities. (nih.gov)
  • 3. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. (nih.gov)
  • 6. Complications of combined radiotherapy and isolated limb perfusion with tumor necrosis factor alpha +/- interferon gamma and melphalan in patients with irresectable soft tissue tumors. (nih.gov)
  • 8. Hyperthermic isolated limb perfusion with tumour necrosis factor-alpha and melphalan as palliative limb-saving treatment in patients with locally advanced soft-tissue sarcomas of the extremities with regional or distant metastases. (nih.gov)
  • 17. Feasibility and efficacy of external beam radiotherapy after hyperthermic isolated limb perfusion with TNF-alpha and melphalan for limb-saving treatment in locally advanced extremity soft-tissue sarcoma. (nih.gov)
  • The objective of the study was to achieve limb salvage in patients with locally advanced soft tissue sarcomas that can only be treated by amputation or functionally mutilating surgery by performing an isolated limb perfusion (ILP) with tumor necrosis factor (TNF) + melphalan (M) as induction biochemotherapy to obtain local control and make limb-sparing surgery possible. (nih.gov)
Present1
  • Asian countries, a number of biosimilar diseases that present major challenges to products such as interleukins, interferons, public health programmes in both devel- erythropoetins, growth factors, hormones, oped and developing countries. (who.int)